Home » Early Postmarketing Focus of ICH Pharmacovigilance Guidance
Early Postmarketing Focus of ICH Pharmacovigilance Guidance
April 8, 2005
The FDA has released a final guidance that describes a method for summarizing identified drug risks, particularly those found early in the postmarketing period. The guidance follows on the heels of other recommendations intended to help firms better monitor drug-safety issues.